ALKERMES | ALKS - Debt



ALKERMES reported $72.68M in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Acadia Pharmaceuticals USD 56.29M 56.29M Jun/2025
ALKERMES USD 72.68M 72.68M Jun/2025
Amgen USD 56.2B 1.18B Jun/2025
Biogen USD 6.59B 296.8M Jun/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Ionis Pharmaceuticals USD 1.42B 169.27M Jun/2025
J&J USD 52.25B 15.62B Mar/2025
Malin Corporation EUR 0 0 Dec/2024
Merck USD 34.84B 2.27B Mar/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Otsuka Holdings JPY 252.7B 63.32B Mar/2025
Pfizer USD 60.93B 1.18B Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025